Oxurion NV of Belgium has appointed Alan Stitt as chief scientific officer to help it develop ophthalmic therapies, with a focus on diabetic macular oedema. Professor Stitt is chair of experimental ophthalmology at Queen’s University of Belfast and has extensively researched the pathogenesis of retinal diseases, especially diabetic retinopathy and age-related macular degeneration. He will continue to perform his university duties on a part-time basis while at Oxurion.
Oxurion NV announced the appointment on 20 January 2021.
Copyright 2021 Evernow Publishing Ltd